论文部分内容阅读
对于不适合手术或放疗复发的晚期乳腺癌患者,内分泌治疗在近二、三十年来日益得到重视.目前以甲孕酮(Medroxyprogestrone acetulewpas,MPA)和甲地孕酮(Megestrol acetate,MA)报道较多.我科自1993年5月～1996年5月间应用化疗和甲孕酮配合化疗治疗晚期乳腺癌84例,现报告如下.材料和方法一、对象 84例晚期乳腺癌患者皆为女性,年龄38～63岁,中位年龄为50岁,均经病理证实,有ECT骨扫描检查,卡氏评分均在50分以上,84例中胸壁复发19例(5例伴溃疡渗液),骨转移65例,84例中卡氏评分在60分以下者14例.全组病人治疗前肝,肾功能和血象均正常.二、方法 化疗方案采用CTX+MTX+5-FU或CTX+ADM+5-FU,剂量参考常规药典,随机分为两组:MPA组(化疗配合MPA为治疗组)与对照组(单纯化疗组).化疗二周期后评价疗效.MPA用法:500mg每日口服一次,化疗前3天服用.用2周休息一周为一疗程.至少二疗程.结果一、近期疗效 按WHO的疗效标准评定疗效.化疗伍甲孕酮治疗晚期乳腺癌胸壁复发及癌性溃疡10例,有效率
For end-stage breast cancer patients who are not suitable for surgery or radiotherapy recurrence, endocrine therapy has received increasing attention in the past two to three decades. Currently, medroxyprogestrone acetulewpas (MPA) and megestrol acetate (MA) have been reported. In our department, from May 1993 to May 1996, 84 cases of advanced breast cancer treated with chemotherapy and medroxyprogesterone combined with chemotherapy were reported as follows. Materials and Methods 1. Subjects 84 patients with advanced breast cancer were all female. Age 38-63 years old, median age 50 years old, confirmed by pathology, ECT bone scan, Karnofsky score above 50 points, 84 cases of chest wall recurrence in 19 cases (5 cases with ulcer exudate), bone Sixty-five cases were transferred to the liver. The liver and renal function and blood were normal before treatment in all patients. The method of chemotherapy was CTX+MTX+5-FU or CTX+ADM+. 5-FU, dose reference conventional Pharmacopoeia, were randomly divided into two groups: MPA group (chemotherapy with MPA as treatment group) and control group (single chemotherapy group). Efficacy was evaluated after two cycles of chemotherapy. MPA usage: 500 mg once daily, Take 3 days before chemotherapy. Use 2 weeks to rest for 1 week. At least 2 courses. Efficacy WHO criteria evaluated. Wu medroxyprogesterone acetate chemotherapy treatment of advanced breast cancer recurrence in 10 cases and ulcer, efficiency